Pyxis Oncology (PYXS) Competitors $1.08 -0.02 (-1.82%) Closing price 04:00 PM EasternExtended Trading$1.11 +0.03 (+2.78%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYXS vs. ALDX, IVA, VOR, ESPR, SCPH, BNTC, HRTX, MREO, TKNO, and ANNXShould you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Aldeyra Therapeutics (ALDX), Inventiva (IVA), Vor Biopharma (VOR), Esperion Therapeutics (ESPR), scPharmaceuticals (SCPH), Benitec Biopharma (BNTC), Heron Therapeutics (HRTX), Mereo BioPharma Group (MREO), Alpha Teknova (TKNO), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. Pyxis Oncology vs. Its Competitors Aldeyra Therapeutics Inventiva Vor Biopharma Esperion Therapeutics scPharmaceuticals Benitec Biopharma Heron Therapeutics Mereo BioPharma Group Alpha Teknova Annexon Aldeyra Therapeutics (NASDAQ:ALDX) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation. Is ALDX or PYXS more profitable? Pyxis Oncology's return on equity of -57.49% beat Aldeyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aldeyra TherapeuticsN/A -72.58% -52.32% Pyxis Oncology N/A -57.49%-45.17% Does the media prefer ALDX or PYXS? In the previous week, Pyxis Oncology had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 2 mentions for Pyxis Oncology and 1 mentions for Aldeyra Therapeutics. Pyxis Oncology's average media sentiment score of 0.89 beat Aldeyra Therapeutics' score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pyxis Oncology 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ALDX or PYXS? Aldeyra Therapeutics currently has a consensus price target of $9.50, indicating a potential upside of 84.11%. Pyxis Oncology has a consensus price target of $9.00, indicating a potential upside of 733.33%. Given Pyxis Oncology's higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Aldeyra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Pyxis Oncology 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility & risk, ALDX or PYXS? Aldeyra Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Which has stronger valuation & earnings, ALDX or PYXS? Aldeyra Therapeutics has higher earnings, but lower revenue than Pyxis Oncology. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAldeyra TherapeuticsN/AN/A-$55.85M-$0.97-5.32Pyxis Oncology$16.15M4.14-$77.33M-$1.59-0.68 Do insiders and institutionals have more ownership in ALDX or PYXS? 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 8.5% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryPyxis Oncology beats Aldeyra Therapeutics on 10 of the 14 factors compared between the two stocks. Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYXS vs. The Competition Export to ExcelMetricPyxis OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.14M$2.53B$5.59B$9.54BDividend YieldN/A1.77%4.73%4.13%P/E Ratio-0.689.1628.8823.87Price / Sales4.14717.24445.9598.86Price / CashN/A159.4135.6858.35Price / Book0.535.078.165.60Net Income-$77.33M$31.61M$3.25B$265.26M7 Day Performance-5.26%-1.85%0.45%-1.00%1 Month Performance-3.14%5.79%8.27%6.09%1 Year Performance-66.77%5.52%30.29%23.81% Pyxis Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYXSPyxis Oncology2.4581 of 5 stars$1.08-1.8%$9.00+733.3%-68.1%$68.14M$16.15M-0.6860News CoverageALDXAldeyra Therapeutics1.4309 of 5 stars$5.32+2.9%$9.50+78.6%+44.5%$309.66MN/A-5.4810Upcoming EarningsIVAInventiva2.7458 of 5 stars$3.04-4.1%$10.40+242.1%+42.7%$302.92M$9.95M0.00100Positive NewsShort Interest ↑Gap UpVORVor Biopharma3.1388 of 5 stars$2.42+10.0%$5.63+132.6%+143.9%$302.40MN/A-1.47140Gap UpESPREsperion Therapeutics4.0551 of 5 stars$1.59+5.3%$7.00+340.3%-27.7%$299.28M$332.31M-1.99200News CoverageEarnings ReportGap UpSCPHscPharmaceuticals3.5307 of 5 stars$5.41-3.4%$14.00+158.8%+22.1%$295.64M$36.33M-2.8330News CoverageUpcoming EarningsBNTCBenitec Biopharma0.9951 of 5 stars$11.02-1.4%$26.00+135.9%+45.1%$293.48M$80K-7.3020HRTXHeron Therapeutics3.8997 of 5 stars$1.86-2.6%$5.00+168.8%-35.5%$291.40M$144.29M-31.00300Positive NewsMREOMereo BioPharma Group1.5221 of 5 stars$1.76flat$7.20+309.1%-57.1%$279.84M$10M-25.1440Upcoming EarningsTKNOAlpha Teknova2.3752 of 5 stars$5.14-0.8%$10.00+94.6%+17.7%$276.82M$37.74M-10.71240Upcoming EarningsANNXAnnexon2.3559 of 5 stars$2.49-0.8%$12.50+402.0%-57.6%$275.38MN/A-2.1160Upcoming Earnings Related Companies and Tools Related Companies ALDX Alternatives IVA Alternatives VOR Alternatives ESPR Alternatives SCPH Alternatives BNTC Alternatives HRTX Alternatives MREO Alternatives TKNO Alternatives ANNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYXS) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PYXS Stock Alerts